Answers are grounded in this paper and cite their sources.
Background This study compares the differences in city-level cardiovascular disease (CVD) drug-lists and investigates their relationship with CVD mortality rates across 16 cities in Anhui province, China. Methods Data on the usage of CVD medicines from 2016 to 2020 in hospitals across various levels in 16 cities and China’s 2018 national list of essential medicines (EMs) were collected and mortality, demographic, environmental data related to CVD were analyzed. The negative binomial mixed-effects model was adopted to compare the differences. A generalized estimating equation was applied to evaluate associations between Anhui city-level drug-lists and mortality over the five years. Results The drug-lists across cities in Anhui province were short. Analysis revealed that the drug-lists of ten cities were shorter than that of the capital city, Hefei. Healthcare expenditure appeared to impact the length of drug-lists. After controlling for per capita GDP, population, widowhood rate, and beds per 1,000 people, it was found that differences in drug-lists were associated with the CVD mortality rate in Anhui Province. Conclusion A shorter city-level CVD drug-list correlates with a higher CVD mortality rate, suggesting the crucial need for local health authorities to revise and establish their own list of essential CVD medicines to meet patient needs.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: